Duration of grade IV neutropenia (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in duration of grade IV neutropenia (lower values signify better… compared with antibiotics alone (low certainty).
1 finding from 1 review
Neutropenia · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel showed no clear difference in neutropenia compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Neutropenia ‐ not reported · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neutropenia · women with recurrent epithelial ovarian cancer
Weekly paclitaxel may leads to lower neutropenia compared with three‐weekly paclitaxel (low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in haematological adverse event: Grade 3/4 neutropenia compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review
Intervention not reported
Letter with fixed appointment versus letter with open invitation to make appointment: uptake of screening · women for cervical screening
The intervention probably leads to higher letter with fixed appointment versus letter with open invitation to… (moderate certainty).
1 finding from 1 review
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with the initial treatment of venous thromboembolism in patients with cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lymphopenia · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in lymphopenia compared with placebo or standard of care (low certainty).
1 finding from 1 review
Neutropenia · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in neutropenia compared with placebo or standard of care (low certainty).
1 finding from 1 review
Thrombocytopenia · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in thrombocytopenia compared with placebo or standard of care (low certainty).
1 finding from 1 review
HCP used 'open questions' · Healthcare professionals working with people who have cancer
1 finding from 1 review
Thrombocytopenia (up to 3 months)n · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) probably leads to higher thrombocytopenia (up to 3 months)n compared with vitamin K antagonist (VKA) (moderate certainty).
1 finding from 1 review
Thrombocytopenia · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in thrombocytopenia (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
Thrombocytopenia · patients with active cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion showed no clear difference in the incidence and severity of toxicities: leukopenia (WHO grade 3 to… compared with no treatment (low certainty).
1 finding from 1 review